Page last updated: 2024-12-05

methyprylon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methyprylon: was heading 1973-94 (see under HYPNOTICS AND SEDATIVES 1963-72); use PIPERIDONES to search METHYPRYLON 1973-94 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4162
CHEMBL ID1200790
CHEBI ID31837
SCHEMBL ID155838
MeSH IDM0224669

Synonyms (73)

Synonym
2,3-diethyl-5-methylpiperidine
3,4-dioxo-5-methylpiperidine
noctan
2, 3,3-diethyl-5-methyl-
methyprylone
metiprilone
nsc30442
methyprylon
nodular
ro 1-6463
noludar
metiprilon
nsc-30442
methyprolon
wln: t6mv dvtj c2 c2 e1
125-64-4
dimerin
3,3-diethyl-5-methylpiperidine-2,4-dione
2,4-piperidinedione, 3,3-diethyl-5-methyl-
brn 0082860
nsc 30442
3,3-diethyl-2,4-dioxo-5-methylpiperidine
2,4-dioxy-3,3-diethyl-5-methylpiperidine
hsdb 3128
einecs 204-745-4
methyprylon [inn]
metiprilona [inn-spanish]
2,4-dioxo-3,3-diethyl-5-methylpiperidine
methyprylone [inn-french]
methyprylonum [inn-latin]
dea no. 2575
3,3-diethyl-5-methyl-2,4-piperidinedione
DB01107
methyprylon (jan/inn)
noludar (tn)
D01150
CHEMBL1200790
methyprylonum
methyprylon [usp:inn:ban]
cut48i42on ,
metiprilona
unii-cut48i42on
AKOS006239549
methprylon
methyprylon [mart.]
methyprylon [orange book]
methyprylon [vandf]
methyprylon [jan]
methyprylon [who-dd]
methyprylon [mi]
methyprylon [hsdb]
gtpl7238
5,5-diethyl-6-hydroxy-3-methyl-2,3,4,5-tetrahydropyridin-4-one
SCHEMBL155838
SIDLZWOQUZRBRU-UHFFFAOYSA-N
DTXSID7023306 ,
CHEBI:31837
Q409558
30590-00-2
methyprylon, (-)-
X66M7YN35V ,
30590-01-3
P66Z3UR32T ,
2,4-piperidinedione, 3,3-diethyl-5-methyl-, (+)-
2,4-piperidinedione, 3,3-diethyl-5-methyl-, (-)-
methyprylon, (+)-
unii-p66z3ur32t
unii-x66m7yn35v
methylprylon
methy prylon
dtxcid303306
methyprylon (mart.)
n05ce02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (90.91)18.7374
1990's1 (2.27)18.2507
2000's1 (2.27)29.6817
2010's1 (2.27)24.3611
2020's1 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.55 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.17%)4.05%
Observational0 (0.00%)0.25%
Other45 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]